gms | German Medical Science

73. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Griechischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

29.05. - 01.06.2022, Köln

Epigenetic characterisation of Hemangioblastomas

Epigenetische Charakterisierung von Hämangioblastomen

Meeting Abstract

  • presenting/speaker Niklas Woltering - Universitätsklinikum Münster, Institut für Neuropathologie, Münster, Deutschland
  • Christian Thomas - Universitätsklinikum Münster, Institut für Neuropathologie, Münster, Deutschland
  • Anne Albers - Universitätsklinikum Münster, Institut für Neuropathologie, Münster, Deutschland
  • Michael Müther - Universitätsklinikum Münster, Klinik für Neurochirurgie, Münster, Deutschland
  • Werner Paulus - Universitätsklinikum Münster, Institut für Neuropathologie, Münster, Deutschland
  • Walter Stummer - Universitätsklinikum Münster, Klinik für Neurochirurgie, Münster, Deutschland
  • Markus Holling - Universitätsklinikum Münster, Klinik für Neurochirurgie, Münster, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 73. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Griechischen Gesellschaft für Neurochirurgie. Köln, 29.05.-01.06.2022. Düsseldorf: German Medical Science GMS Publishing House; 2022. DocV179

doi: 10.3205/22dgnc173, urn:nbn:de:0183-22dgnc1730

Published: May 25, 2022

© 2022 Woltering et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.


Outline

Text

Objective: Hemangioblastomas (HBs) of the central nervous system are rare tumors and occur sporadically or as a manifestation of von Hippel-Lindau (vHL) disease. Despite their benign nature, the clinical course is variable. Therefore, a better knowledge of molecular factors involved in HB tumor biology may aid in identifying patients at risk for recurrence.

Methods: DNA methylation profiling was performed in a series of 47 HBs. Clinical data were retrieved retrospectively from medical records. Histologic subtypes (reticular and cellular) were extracted from the pathology reports. All samples were analyzed on the Infinium Methylation EPIC BeadChip to determine the methylation status of ca. 850.000 CpG-Sites and were performed in R 4.0.3 and 4.10. After preprocessing with minfi and quality checks, the most variable CpG-Sites were selected by standard deviation, and dimensionality reduction was performed with tSNE and UMAP. Consensus clustering was performed using the COLA-Package to determine the number of subgroups.

Results: The series comprised 29 males and 18 females, including 28 individuals with vHL disease. Median age of patients with vHL associated tumors was significantly younger (39.6 vs. 55.7 years, p= 0.00048, t-test). Thirty tumors occurred in the cerebellum, 8 in the brainstem, while 8 HBs were spinal. Dimensionality reduction and unsupervised clustering of DNA methylation data separated the tumors into two distinct and stable subgroups (30 group 1 and 17 group 2). The two subgroups were associated with tumor location and the histologic subtype (p=0.00000001, Chi-square test). Reference-free deconvolution revealed four latent methylation components, two of which were associated with an endothelial signature.

Conclusion: Results indicate DNA methylation might play a role in the biology of HBs. No difference could be determined between sporadic and vHL-associated HBs as well as cyst-forming vs. non-cyst-forming HBs. There is strong evidence that cerebellar HBs significantly differ from non-cerebellar hemangioblastoma in the spinal column and brainstem. Further examination of latent methylation components of a larger cohort is warranted.